The remarkably increase in the survival of mice with CT26 tumours treated with the combination of αCTLA-4 with redaporfin-PDT can be assigned to the high surface expression of CD80 and unchanged expression of CTLA-4 post-PDT. This evidence concerns the gene CD80 and neoplasm.